SCHEMBL6942857

SCHEMBL6942857

Cc1ccc(S(=O)(=O)O)c(C2CCC(NC(=O)OC(C)(C)C)CC2)c1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 1/20 0.44
JAK1 P23458 1/20 0.44
TYK2 P29597 1/20 0.44
JAK3 P52333 1/20 0.44
KDM1A O60341 1/20 0.43
MAOB P27338 1/20 0.43
EPHX2 P34913 3/20 0.42
KAT6A Q92794 1/20 0.41
KAT5 Q92993 1/20 0.41
DRD2 P14416 2/20 0.39
KMT2A Q03164 2/20 0.39
LIPG Q9Y5X9 1/20 0.38
MAPT P10636 1/20 0.38
CTSL P07711 1/20 0.37
CTSB P07858 1/20 0.37
CTSS P25774 1/20 0.37
CTSK P43235 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
BTK Q06187 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29062245 1.00 JAK2 (0.44) JAK2JAK1TYK2JAK3KDM1A
SCHEMBL28851424 1.00 JAK2 (0.44) JAK2JAK1TYK2JAK3KDM1A
SCHEMBL29172685 0.91 KMT2A (0.41) JAK2JAK1TYK2JAK3KDM1A
SCHEMBL28570368 0.89 JAK2 (0.43) JAK2JAK1TYK2JAK3KDM1A
SCHEMBL30421230 0.89 JAK2 (0.43) JAK2JAK1TYK2JAK3KDM1A
SCHEMBL28479502 0.86 JAK2 (0.41) JAK2JAK1TYK2JAK3KDM1A
SCHEMBL28397690 0.84 EPHX2 (0.44) EPHX2KMT2AMAPTL3MBTL1
SCHEMBL6942861 0.81 JAK2 (0.44) JAK2JAK1TYK2JAK3KDM1A
SCHEMBL9101971 0.81 PTGDR2 (0.39) EPHX2DRD2KMT2AMAPTL3MBTL1
SCHEMBL2217850 0.77 PTGDR2 (0.46) EPHX2KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12583825-B2 Benzo[h]quinazolin-4-amine and thieno[3,2-h]quinazolin-4-amine derivatives for the treatment of cancer Redona Therapeutics, Inc. (US) 2026-03-24 US disclosed
US-20230365509-A1 BENZO[H]QUINAZOLIN-4-AMINE AND THIENO[3,2-H]QUINAZOLIN-4-AMINE DERIVATIVES FOR THE TREATMENT OF CANCER Redona Therapeutics, Inc. 2023-11-16 US disclosed
CN-116490186-A Compounds for targeted degradation of RET C4医药公司 2023-07-25 CN disclosed
CN-111032641-A Substituted 5-cyanoindole compounds and uses thereof 诺华股份有限公司 2020-04-17 CN disclosed
US-6753445-B2 14-O-((CYCLOALKYL-SULFANYL)ACETYL)-, 14-O-((CYCLOALKYL-ALKYL-SULFANYL)ACETYL)-, 14-O-((CYCLOALKOXY)ACETYL)- AND 14-O-((CYCLOALKYL-ALKOXY) ACETYL) MUTILINS; MICROBIOCIDES BIOCHEMIE GESELLSCHAFT M.B.H. (AT) 2004-06-22 US disclosed
US-20030162831-A1 Pleuromutilin derivatives having antibacterial activity Nabriva Therapeutics GmbH (AT) 2003-08-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230365509-A1 BENZO[H]QUINAZOLIN-4-AMINE AND THIENO[3,2-H]QUINAZOLIN-4-AMINE DERIVATIVES FOR THE TREATMENT OF CANCER H1-10, H1-3, H1-0 JAK2 316/4885JAK1 603/4885TYK2 520/4885
US-20030162831-A1 Pleuromutilin derivatives having antibacterial activity MLN, PLEC, ST14 JAK2 3284/4885JAK1 4579/4885TYK2 4010/4885
US-12583825-B2 Benzo[h]quinazolin-4-amine and thieno[3,2-h]quinazolin-4-amine derivatives for the treatment of cancer H1-3, RB1, H1-2 JAK2 221/4885JAK1 539/4885TYK2 102/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.